Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Delaunay, M.; Cadranel, J.; Lusque, A.; Meyer, N.; Gounaut, Valérie; Moro-Sibilot, D.; Michot, J.; Raimbourg, J.; Girard, N.; Guisier, F.; Planchard, D.; Metivier, A.; Tomasini, P.; Dansin, É.; Pérol, M.; Campana, M.; Gautschi, O.; Früh, M.; Fumet, J.; Audigier-Valette, C.; Couraud, S.; Dalle, S.; Leccia, M.; Jaffro, M.; Collot, S.; Prévôt, G.; Milia, J.; Mazières, J.

doi:10.1183/13993003.00050-2017

Public

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Shared by NobleBlocks on Aug 1, 2017 • 12:00 AM UTC

Authors:

M. Delaunay

J. Cadranel

A. Lusque

Abstract

Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as a rare but potentially severe event. Between December 2015 and April 2016, we conducted a retrospective...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!